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In the majority of infants and children with constipa-
tion, no obvious cause can be identiﬁed. A rare cause 
of constipation is Hirschsprung disease (HD). HD is 
characterized by the absence of ganglion cells from 
the anorectum for a variable length up to the duode-
num. The extent of the aganglionic segment varies, but 
in most patients the lesion does not extend beyond 
the rectum and sigmoid colon. This review focuses on 
the passage of meconium, the recognition of HD, and 
new insights in its pathophysiology and genetics. The 
authors also provide a summary of the diagnostic evalu-
ation and treatment of HD in infancy and childhood.
Introduction
In healthy term infants, the passage of meconium occurs 
in 95% within 24 hours and in 99% within 48 hours of 
birth [1,2]. This percentage, however, drops dramatically 
to 66% in preterm infants (s 32 weeks gestation) and 
those born with low birth weight (<2500 g) infants [1,2]. 
Most likely, this delay simply reflects impaired matura-
tion, but it should alert the clinician as it may be the first 
sign of a defecation disorder.
Especially in premature infants, delayed maturation 
of the motor mechanisms of the gut might play a role in 
delayed passage of meconium. In this fragile group of 
infants, such delayed passage may cause significant mor-
bidity (intestinal perforation) and even mortality. At first 
instance, a “wait and see” policy is often used in these 
infants. However, if these infants develop feeding prob-
lems and abdominal distention, enemas, laxatives, or 
both are given to relieve colonic distention and continued 
until a normal defecation pattern has been developed. In 
those infants who do not develop a normal defecation 
pattern in the following weeks, Hirschsprung disease 
(HD) should be excluded.
To date, the development of colorectal motility is 
poorly understood in preterm infants. Some authors 
suggest that preterm infants may have delayed transit of 
luminal contents through the colon; however, colonic 
motility has never been directly assessed in these infants 
[3–5]. Recently, Kenny et al. [6] demonstrated that 
delayed passage of meconium may result from a delayed 
maturation of interstitial cells of Cajal. Interstitial cells of 
Cajal function as pacemaker cells coordinating the elec-
tromechanical activity of the gut [7,8].
Factors other than motility may also contribute to the 
delay in meconium passage. The meconium of premature 
infants differs in composition (glycoprotein, saccharides, 
calcium, copper, iron, and phosphorus), making it more 
viscous and thus more difficult to be expelled [9].
Delayed passage of meconium may result from 
the absence of the enteric nervous system, as typically 
described in HD. This is a developmental disorder of the 
enteric nervous system characterized by the absence of 
ganglion cells along a variable portion of the distal intes-
tine starting from the internal anal sphincter. More than 
90% of infants with HD fail to pass meconium within 
24 hours after birth.
Finally, delayed passage of meconium might also be 
the first sign of functional constipation. This is a com-
mon disorder, and symptoms vary from a relatively mild 
short-lived bowel problem to severe chronic constipation 
with fecal impaction and fecal incontinence [10••,11••]. 
The pathophysiology underlying functional constipation 
is undoubtedly multifactorial and not well understood 
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[10••,11••]. Clearly, functional constipation can result 
from abnormal function of the regions involved, includ-
ing the colon, the rectum, and the sphincter complex. 
No specific organic cause can be found in approximately 
90% of the infants [11••]. We will not discuss functional 
constipation further in this review. Rather, we focus on 
the latest findings regarding the pathophysiology, symp-
tomatology, diagnostic evaluation, and treatment of HD 
in infancy and childhood.
Hirschsprung Disease
HD is a developmental disorder of the enteric nervous 
system. It is characterized by the absence of ganglion 
cells along a variable portion of the distal intestine, 
which results in functional obstruction caused by dys-
motility of the diseased segment, lack of propagation 
of peristaltic waves into the aganglionic colon, and 
abnormal or absent relaxation of this segment and of the 
internal anal sphincter [12,13].
Clinical presentation
Approximately 80% to 90% of all patients with HD have 
typical clinical symptoms and are diagnosed during the 
neonatal period. Delayed passage of meconium is the 
cardinal symptom in neonates with HD. Over 90% of 
patients fail to pass meconium within 24 hours after birth 
[13]. This finding strongly contrasts with results in healthy 
neonates, who pass meconium within 24 hours in 95% 
of the cases. However, in a recent study of 111 infants 
suspected of having HD, delayed passage of meconium 
in itself did not seem to be useful as a means to differ-
entiate between HD and functional constipation [14••]. 
More than 40% of the children evaluated in this study 
with functional constipation and approximately 30% of 
healthy preterm infants had delayed meconium produc-
tion (Table 1). In patients presenting with delayed passage 
of meconium and other important clinical signs, such as 
vomiting and abdominal distention, however, rapid diag-
nostic tests are necessary.
The usual presentation of HD in the neonatal period is 
constipation, abdominal distention, and vomiting during 
the first days of life (Table 2). However, about a third of 
the babies with HD present with diarrhea without obvious 
distention and vomiting. In these infants, one should be 
alert because diarrhea in HD is in most cases a symptom 
of enterocolitis and remains the most common cause of 
morbidity and mortality in this disease. Adequate therapy 
is necessary to prevent toxic megacolon, a life-threatening 
condition characterized by the sudden onset of marked 
abdominal distention, bile-stained vomiting, fever, and 
signs of dehydration and shock.
In many cases of HD, a rectal examination brings 
passage of meconium and relief of the acute intestinal 
obstruction. These babies may have normal bowel move-
ments for a few days or weeks and then show signs and 
symptoms of intestinal obstruction. Fecal incontinence, 
often present in functional constipation in children, is 
often absent in children with HD (Table 2). However, in 
a minority of patients, HD may be manifested as chronic 
constipation with or without abdominal distention and is 
manageable with changes in diet and laxatives, supposito-
ries, or enemas. Thus, it is clear that early differentiation 
between HD and functional constipation is necessary to 
prevent severe complications of HD.
Epidemiology and genetics
HD is a rare disorder, and its incidence is estimated to be 
approximately one in 5000 live births, with a male-to-female 
ratio of 4 to 1.15. The majority of children with HD (93%) 
are born at term with a normal birth weight [13].
The length of the affected segment varies and appears 
to determine the recurrence risk and mode of inheritance. 
Short-segment or classic HD, involving the rectum and 
sigmoid, accounts for 75% to 80% of cases [15–17]. In 
the remainder of cases, the aganglionic segment extends 
more proximally and may even affect the entire colon. In 
cases of total colonic aganglionosis, a familial incidence 
of 15% to 21% has been reported, increasing up to 50% 
in total intestinal aganglionosis [15]. As the length of 
the aganglionic segment increases, the recurrence risk to 
siblings increases [18].
Although genetic factors are definitely involved, there 
is no clear pattern of inheritance, and most investigators 
have found a sex-modified multifactorial mode of inheri-
tance [18,19••]. So far, ten genes and five loci for HD 
susceptibility have been identified (Table 3).
Results from many studies indicate that the recep-
tor tyrosine kinase (RET) is the major susceptibility 
gene for HD [20–22]. Approximately 50 RET mutations 
Table 1. Patient characteristics
Total group HD FC P-value 
(n=111) (n=28) (n=83) HD vs FC  
Boys, % 60 68 58 0.35
Prematurity, % 17 4 22 0.03
Delayed (>24-hour) meconium passage, % 54 81 44   0.001
Median defecation frequency/week (range) 2.0 (0.0–49.0) 0.5 (0.0–24.0) 2 (0.0–49.0) 0.30
HD—Hirschsprung disease; FC—functional constipation.
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have been reported in HD patients, accounting for 50% 
of familial and 15% to 20% of sporadic cases of HD 
[18,19••]. RET mutations are also associated with mul-
tiple endocrine neoplasia type 2 (MEN2) and familial 
medullary thyroid carcinoma [23,24].
In the majority (70%), however, HD occurs as an 
isolated trait (nonsyndromatic HD). Association with 
chromosomal abnormalities, other birth defects, and 
syndromes with mendelian patterns of inheritance occurs 
in 30% (syndromatic HD). A chromosomal abnormal-
ity is associated with HD in 12% of cases, with trisomy 
21 (Down syndrome) by far the most frequent (>90%), 
involving 2% to 10% of ascertained HD cases [25]. 
Associated congenital anomalies are found in 18% of HD 
patients and include central nervous system anomalies, 
genitourinary abnormalities, and other gastrointestinal 
malformations. Furthermore, HD has been reported in 
several known syndromes including Smith-Lemli-Opitz 
syndrome, MEN2, X-linked hydrocephalus, congenital 
central hypoventilation syndrome, and Waardenburg 
syndrome type 4 [25].
Etiology and Pathogenesis
HD is characterized by the absence of ganglion cells in 
the myenteric (Auerbach) and submucosal (Meissner) 
plexus of the distal bowel extending proximally from 
the internal anal sphincter for varying distances. The 
absence of ganglion cells has been attributed to failure 
of migration of neural crest cells between the fifth and 
twelfth week of gestation [26]. The neurons and glia of 
the enteric nervous system are all derived from precur-
sor cells from the central nervous system primordium. 
Neural crest cells are produced from the entire length of 
the neural axis, but only certain tightly defined regions 
of the neural crest give rise to the enteric nervous system. 
These precursor cells first migrate from the central ner-
vous system primordium into the oral and anal ends of 
the intestinal tract early in embryonic life. Subsequently, 
these cells migrate along the gut to colonize the entire 
intestine. The enteric nervous system precursor cells dif-
ferentiate into a range of neuron types and glial cells and 
form the complex circuitry necessary for enteric nervous 
system function [27,28••,29••].
HD is regarded as a neurocristopathy, defined as a 
syndrome or tumor that arises due to an abnormality in 
neural crest cell development. In HD, the enteric ner-
vous system is inadequately formed due to the arrest 
of vagal neurocrest cell emigration to the hindgut. The 
earlier the arrest of migration, the longer the agangli-
onic segment. Aganglionosis is generally limited to the 
rectum (75%), although in rare cases the aganglionosis 
may affect the entire colon, the colon and small intes-
tine, or the entire gut [15–17].
The absence of enteric ganglia containing cho-
linergic neurons, interneurons, and nonadrenergic, 
noncholinergic neurons is considered the most impor-
tant pathologic finding in HD. The absence of ganglion 
cells is accompanied by increased cholinergic and 
adrenergic nerve fibers because regulation of the devel-
opment of these nerve fibers is lacking [30]. These 
abnormalities in innervation explain the inability of the 
aganglionic segment to relax. The wave of relaxation 
normally preceding each propulsive contraction does 
not occur, and furthermore, the rectoanal inhibitory 
reflex (RAIR) to rectal distention is lacking [30].
RAIR
The presence of the RAIR is a key factor in the normal def-
ecation process. The RAIR is elicited by distention of the 
rectal wall, which stimulates mechanoreceptors located in 
the rectum. This leads to activation of intramural inhibit-
ing neurons, located in the myenteric plexus, relaxing the 
internal anal sphincter (Fig. 1) [31]. When defecation is 
not desirable, the external anal sphincter, with the help of 
the pelvic floor, remains contracted until the rectal wall 
has adapted to the increased rectal volume.
Results from animal studies have shown that nitric 
oxide is the main inhibitory neurotransmitter released by 
these neurons [32]. Blockade of nitric oxide biosynthesis 
reduced the relaxation of muscle strips of the internal 
anal sphincter and impaired the RAIR [32,33]. 
Table 2. Presenting symptoms: chronic constipation versus classic Hirschsprung disease
Symptoms Chronic constipation Hirschsprung disease
Fecal incontinence Common Rare
Abdominal pain Occasionally Common
Stool size Large Normal
Failure to thrive Rare Common
Stool-withholding behavior Common Rare
Abdominal fecal mass Common Rare
Ampullary feces Common Rare
Anorectal examination Dilated ampulla Narrow
Enterocolitis Never Occasionally
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Recent evidence has shown that the nitrergic innerva-
tion is dependent on the presence of an intact network 
of interstitial cells of Cajal, cells of mesenchymal origin 
distributed within the tunica muscularis of the gastro-
intestinal tract [34,35]. The interstitial cells of Cajal 
function as pacemaker cells coordinating the electro-
mechanical activity of the gut [7,8]. A second subset of 
interstitial cells of Cajal located in the muscular layer has 
been shown to mediate the nitrergic neurotransmission in 
the stomach and lower esophageal sphincter [34]. Intersti-
tial cells of Cajal have also been shown to play a role in 
the afferent limb of the RAIR [36].
Diagnosis
Due to the risk of significant complications of HD, it is 
clinically important to differentiate infants with HD from 
infants with functional constipation. Contrast enema, 
anorectal manometry, and rectal suction biopsy are the 
most common tests used in the diagnostic work-up of HD. 
Because the sensitivity and specificity of these tests varies 
widely [37], the appropriate diagnostic approach for HD is 
still a matter of debate [38–41]. In most centers, however, 
the reference standard for diagnosing HD is a full-thickness 
rectal biopsy. This test provides the most definitive answer, 
but it is invasive and requires general anesthesia. 
Contrast enema
Contrast enema is one of the first investigations used 
to evaluate lower intestinal obstruction in infancy and 
to differentiate HD from other possible diagnoses, such 
as meconium ileus, distal atresias, and meconium plug 
syndrome [42]. To imitate the natural situation, it is 
important to perform a contrast enema in the unpre-
pared colon, without prior enemas or disimpaction 
[43]. However, even in experienced hands a contrast 
enema is difficult to evaluate. The classic finding in 
patients with HD is a caliber change between the small 
or normal-sized distal aganglionic segment and the 
dilated proximal ganglionic bowel [44]. In some cases, 
an abnormal mucosal pattern may be observed, indi-
cating the presence of enterocolitis. However, in young 
children or in cases of total aganglionosis, the caliber 
change is more difficult to demonstrate [40,45–47]. On 
the other hand, rectal enemas and even digital rectal 
examination may decompress the distended proximal 
Table 3. Genes involved in HD
Gene Phenotype Inheritance Study
RET 10q11.2 Nonsyndromatic Dominant, incomplete penetrance [67]
Hirschsprung-MEN2A/FMTC
GDNF 5p13 Nonsyndromatic Non-mendelian [68]
Neurturin 19p13 Nonsyndromatic Non-mendelian [69]
EDNRB 13q22 Shah-Waardenburg Recessive [70]
Nonsyndromatic Dominant (de novo in 80%)
EDN3 20q13 Shah-Waardenburg Recessive [71]
Nonsyndromatic Dominant, incomplete penetrance
SOX10 22q13 Shah-Waardenburg Dominant (de novo in 75%) [72]
ECE-1 1p36 Congenital heart malformation De novo dominant [73,74]
ZFHX1B* 2q22 Mowat-Wilson De novo dominant [75]
KIAA1279 10q21.3-q22.1 Goldberg-Shprintzen Recessive [76]
PMX2b 4p12 Congenital central hypoventilation 
syndrome (CCHS)
De novo in 90% [77]
Unknown 3p21 Nonsyndromatic, S-HSCR Non-mendelian [78]
Unknown 9q31 Nonsyndromatic, L-HSCR Dominant, incomplete penetrance [79]
Unknown 19q12 Nonsyndromatic, S-HSCR Non-mendelian [78]
Unknown 16q23 Shah-Waardenburg Non-mendelian [70]
Unknown 4q31.3-q32.3 Nonsyndromatic, S-HSCR Autosomal dominant, incomplete 
penetrance
[80]
*ZFHX1B encodes Smad-interacting protein-1 (SMADIP1 or SIP1), and PMX2b, paired mesoderm homeobox gene. 
ECE1—endothelin-converting enzyme 1; EDN3—endothelin-3; EDNRB—endothelin receptor B; FMTC—familial medullary thyroid 
carcinoma; GDNF—glial cell line–derived neurotropic factor; HD—Hirschsprung disease; L-HSCR—long segment Hirschsprung disease; 
MEN2A— multiple endocrine neoplasia type 2a, RET—rearranged during transfection; S-HSCR—short-segment Hirschsprung disease, 
SOX10—sex determining region Y-related HMG-box 10; ZFHX1B—zinc ﬁnger homeo box 1B. 
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bowel with distortion of the caliber change, leading 
to false-negative test results. Contrast enema might be 
presumed helpful for the surgeon to assess the local-
ization of the caliber change and thus the length of 
the aganglionic segment. However, the assessment of 
length of aganglionosis has often been questioned in 
the literature [48].
Anorectal manometry
Anorectal manometry is a relatively safe and noninvasive 
technique. It measures pressures in the anorectal region 
and provides a way to quantify the function of the inter-
nal and external sphincters. Although this technique 
is widely used, lack of standardization in methodology 
(open-tipped perfusion, closed triple-balloon, pressure 
transducers) has resulted in inconsistent data [49,50].
The main indication to perform this procedure is 
for demonstration of the presence of the RAIR (Fig. 1). 
The RAIR can be elicited by rectal balloon distention 
with small volumes of air (1–60 mL). Term and pre-
mature infants older than 26 weeks in postmenstrual 
age have a normally developed RAIR to rectal disten-
tion [52,53]. False-positive test results may ensue from 
insufficient inflation of the balloon in children with a 
megarectum, as larger volumes are required in these 
children to elicit a RAIR [53]. Furthermore, such tech-
nical factors as air leak in the circuit or an incorrectly 
positioned catheter in the sphincter complex can also 
cause false-positive or negative test results. Artifacts 
are common in agitated or crying infants, and results 
should be interpreted with caution.
Histology
Classically, the diagnosis of HD is based on histochemi-
cal evaluation of the rectum. This examination typically 
shows absence of ganglion cells in the submucous and 
myenteric plexus and an increase in acetylcholinesterase 
activity in the parasympathetic nerve fibers of the lamina 
propria mucosa, muscularis mucosa, and circular muscles 
(Fig. 2) [44]. Two methods are used to obtain tissue for 
histochemical evaluation.
Rectal suction biopsy
Rectal suction biopsy can be performed with no anes-
thetic and little risk; several biopsies are taken above 
the anal margin (at 2 and 4 cm from the anal margin, 
anterior and posterior). This technique should reduce the 
risk of sampling from the normal aganglionic anal canal 
or of missing an ultra-short segment of HD. The instru-
ment used for biopsies must be sharp to get good-sized 
specimens. However, because the specimens are small 
compared with full-thickness specimens, the examina-
tion remains difficult even for experienced pathologists 
[45]. The introduction of staining for acetylcholinesterase 
activity on a suction biopsy has made the morphologic 
diagnosis of HD easier and more reliable [44,54]. Pos-
sible causes for false-negative test results are sampling 
error, superficial biopsy material that lacks muscularis 
mucosa, technical variations in staining technique, and 
the relative experience of individual pathologists. Fur-
thermore, in neonates a false-negative result may be 
caused by the immaturity of the submucous plexus [44]. 
Possible complications of this procedure are perforation, 
bleeding, and infection.
Full-thickness biopsy
The classic approach is full-thickness biopsy of rectal 
mucosa and underlying muscle. However, this method 
requires general anesthesia and suturing of the biopsy site 
[55]. As with the suction biopsy, possible complications 
of this procedure are perforation, bleeding, and infection. 
Absence of ganglion cells in a full-thickness biopsy con-
firms the diagnosis of HD.
Sensitivity and specificity of diagnostic tests
In a recent large prospective study in 111 patients, de 
Lorijn et al. [14••] showed that rectal suction biopsy had 








(sleeve) 30 mm Hg
10 seconds
Air insufﬂation
Figure 1. Anorectal pressure recordings in 
a 29-week-old premature infant showing 
rectal inhibitory reflex (RAIR) elicited by 
air insufflation. 
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values were not significantly different from those in con-
trast enema (sensitivity=76%, P=0.29; specificity=97%, 
P=0.50) or from anorectal manometry (sensitivity=83%, 
P=0.69; specificity=93%, P=0.06). Inconclusive test 
results occurred in eight infants with contrast enema 
(3 with HD), in 15 infants with anorectal manometry due 
to agitation (5 with HD), and in two infants with rectal 
suction biopsy (1 with HD). The authors concluded that 
rectal suction biopsy is the most accurate test to diagnose 
Hirschsprung disease, although differences did not reach 
statistical significance. Moreover, rectal suction biopsy 
also had the lowest rate of inconclusive test results. In our 
opinion, the value of a contrast enema in the evaluation 
of HD is limited because of its fairly low sensitivity and 
high radiation exposure. Only if the diagnosis of HD has 
been established, contrast enema may be helpful for the 
surgeon to assess the localization of the caliber change 
and thus the length of the aganglionic segment.
Differential diagnosis
Other causes of intestinal obstruction should be considered 
when abdominal distention and failure to pass meconium 
occur in a newborn infant. The following organic disor-
ders are important to exclude: meconium ileus (resulting 
from cystic fibrosis); intestinal malformations such as 
lower ileal and colonic atresia or congenital strictures; 
malrotation (which requires immediate surgery); and 
functional intestinal obstruction resulting from maternal 
infection, maternal intoxication, or congenital hypothy-
roidism. Furthermore, enteric nervous system anomalies, 
such as hypoganglionosis, hyperganglionosis, intestinal 
neuronal dysplasia type B, and immaturity of the submu-
cous and myenteric plexus, should be considered. These 
anomalies lead to chronic intestinal pseudoobstruction 
and can be differentiated from HD by histologic staining. 
A full-thickness biopsy is needed to diagnose hypergan-
glionosis and intestinal neuronal dysplasia type B (giant 
ganglia), and lactic dehydrogenase reaction is needed to 
verify the maturity of the ganglia [44].
Treatment
Once the diagnosis of HD has been confirmed by rectal 
biopsy, the infant should be prepared for laparotomy. 
When rectal biopsy is inconclusive, the clinical picture will 
determine the persistence of repeat biopsy attempts and, 
if necessary, full-thickness biopsy sampling to confirm 
the clinically suspected diagnosis of HD. If the newborn 
has enterocolitis complicating HD, the child will require 
correction of dehydration and electrolyte imbalance by 
infusion of appropriate fluids. It is essential to decompress 
the bowel immediately and permanently. Deflation of the 
intestine may be carried out initially by rectal irrigations 
through a cannula. When the baby is clinically stable a 
colostomy will be performed.
For many years, the vast majority of cases of HD have 
been diagnosed in the neonatal period [56]. Laparotomy 
is generally performed between 6 and 12 months of age. 
The advantages of operating in the first year are that the 
colonic dilatation can be quickly controlled by washouts 
and at operation the caliber of the pull-through bowel is 
nearly normal, allowing for an accurate anastomosis that 
minimizes leakage and cuff infection [57,58].
A number of different operations have been described for 
the treatment of HD. Currently, many centers are perform-
ing one-stage pull-through procedures in newborn infants 
with minimal morbidity and encouraging results [59,60].
The basic principle is to bring the ganglionic bowel 
down to the anus. During surgery, biopsies for frozen sec-
tions are taken to determine the level of transition, and a 
colostomy is placed proximal to the transition zone. The 
three most commonly used operation techniques are the 
rectosigmoidectomy developed by Swenson, the retrorec-
tal transanal approach developed by Duhamel, and the 
endorectal procedure developed by Soave. Recent innova-
tions are the transanal endorectal pull-through and the 
laparoscopic approach to all three techniques. 
A recent long-term study in 41 patients with HD 
comparing transanal pull-through to transabdominal 
pull-through showed a significantly better continence 
outcome for the abdominal approach [59]. However, the 
stooling pattern and enterocolitis scores were somewhat 
better for the latter group.
An excellent review by Geerdes et al. [60] provides 
more detailed information about surgical procedures.
Prognosis after surgery
Surgical reconstruction for HD provides near-normal 
gastrointestinal function for the majority of children [61]. 
In general, the most commonly encountered postoperative 
problems include constipation (more often with Duhamel 
technique), incontinence, enterocolitis (more often with 
Swenson and Soave technique), and the overall impact of 
the disease on lifestyle [60]. Other complications, such as 
fistulae and obstructions, are quite rare [62,63].
Although gastrointestinal function improves after 
surgery, long-term follow-up reveals significant residual 
Figure 2. Increased acetylcholinesterase activity in the agangli-
onic bowel.
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problems. Unfortunately, most reviews of HD are ham-
pered by short follow-up periods that may not adequately 
reflect long-term outcome and lifestyle. One of the more 
complete studies on this subject was performed by Moore 
et al. [64,65]. These authors described the overall quality of 
life as quite good, with 94% of children becoming well-
adjusted members of society. Although patients had low 
weight for their age, this generally corrected with time. 
Additionally, developmental milestones and school per-
formance were satisfactory in most patients (95% and 
82%, respectively). Clearly, patients with poor functional 
outcome have a greater tendency to have more psychoso-
cial problems. In general, Moore et al. [64,65] were quite 
positive about quality of life issues in their review of 
children after an endorectal procedure. Factors that were 
predictive of poor quality of life were fecal incontinence 
(2.5%–13.6%) and poor family report.
Another recently published study showed that patients 
with HD encountered more “overall” physical health prob-
lems compared with healthy subjects, but HD patients did 
not show additional pain or limitations in functioning due 
to physical problems [66]. Psychosocial functioning had 
the most important effect on the quality of life of patients 
with HD, whereas fecal incontinence and constipation 
had almost no effect on their quality of life.
Conclusions
HD is a rare gastrointestinal disorder in which delayed 
passage of meconium is the key characteristic. Early rec-
ognition and adequate therapy are necessary to prevent 
toxic megacolon. Rectal suction biopsy is the most accu-
rate test to diagnose HD and has the highest sensitivity 
and specificity. A negative rectal suction biopsy virtually 
rules out the diagnosis of HD. However, if symptoms of 
severe constipation persist and clinical suspicion remains 
high, further evaluation (anorectal manometry and con-
trast enema) is necessary.
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